Malignant spiradenoma in a patient with Recklinghausen syndrome: a potential association

Stefania Erra *, Corinna Pizio and Ennio Nano

Surgical Pathology Department, Santo Spirito Hospital, Viale Giolitti 2, Casale Monferrato, Italy.
 
Research Article
GSC Biological and Pharmaceutical Sciences, 2020, 12(03), 236-240.
Article DOI: 10.30574/gscbps.2020.12.3.0306
Publication history: 
Received on 20 September 2020; revised on 29 September 2020; accepted on 30 September 2020
 
Abstract: 
Recklinghausen syndrome or neurofibromatosis type 1(NF1) is a hereditary condition transmitted with a dominant autosomal inheritance pattern. It’s a systemic disorder characterized by involvements of skin, nerves, bone, soft tissues, iris and nervous system. Specifically a mutation of one allele of the oncosoppressor gene NF1 is the cause of the syndrome. Manifestations of neurofibromatosis include: benign tumors like neurofibromas, pheocromocytoma, juvenile xanthogranulomas, Lisch nodules, café-au-lait macules and freckles. Neurofibromatosis also correlates with an increased risk for malignant tumors like malignant melanoma, leukemia, brain gliomas. In this manuscript we report the association of NF1 with a malignant spiradenoma. A literature review has been made to investigate a possible correlation between these two entities.
 
Keywords: 
Neurofibromatosis type 1; Malignant spiradenoma; Neurofibromin; Ras-pathway; NF-kB pathway
 
Full text article in PDF: 
Share this